leisure time -WSS

leisure time

author：entertainment 2025-09-29 22:51:28 - browse：6587

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： In new study, freeze

Wikipedia

focus

WSS

2023 Nobel Prize in Medicine goes to Karikó and Weissman

The Karikó problem: Lessons for funding basic research

Lawsuit highlights wrinkle for disputes over surprise medical bills

The Karikó problem: Lessons for funding basic research

What will Novo Nordisk's VC do with its influx of cash?

The Karikó problem: Lessons for funding basic research

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Psychedelics group wrestles with new pharma identity

Body of missing toddler recovered in Delaware River days after flood: Police

Dobbs anniversary: the lost opportunity of abortion as health care

New oral drug delivery patch is modeled after octopus tentacles

Peter Hotez and the public health issue of online harassment

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Cancer drug shortages should be causing more outrage

7 of the most gruesome medical devices in history

United colonoscopy coverage change 'may cost lives,' doctors say

How artificial intelligence is being used to detect, treat cancer

focus

AbbVie dramatically boosts its spending on lobbying

What we owe ALS patients — and why one company fell short

CDC picks Alphabet's Verily for wasterwater surveillance contract

Why an extreme heat and wildfire smoke combination can be so dangerous

Health insurers' Q3 question: how much care are people getting?

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Wikipedia

focus

focus

focus